Meeting
2023 ASCO Annual Meeting
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.
Authors
Joaquim Bellmunt
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Joaquim Bellmunt , Jeanny B. Aragon-Ching , Miguel Ángel Climent , Srikala S. Sridhar , Thomas Powles , Paul Cislo , Elisabete Michelon , Alessandra Di Pietro , Petros Grivas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02603432
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4516)
DOI
10.1200/JCO.2023.41.16_suppl.4516
Abstract #
4516
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).
First Author: Jeanny B. Aragon-Ching
Poster
2022 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
First Author: Begoña Pérez-Valderrama
Poster
2022 ASCO Annual Meeting
Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100.
First Author: Joaquim Bellmunt
Poster
2021 ASCO Annual Meeting
Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.
First Author: Petros Grivas